Virinchi Ltd Allots 74 Lakh Warrants to Vivo Bio Tech at ₹28/Share
Virinchi Limited approved the allotment of 74 Lakh convertible equity warrants to Vivo Bio Tech Limited at ₹28 per warrant. The company received 25% of the issue price, amounting to ₹5.18 crore. Warrants are convertible into equity shares within 18 months.
The allotment of warrants is a form of equity fundraising that will increase the company's capital base upon conversion. While positive, the immediate impact is limited as full conversion is pending and the amount raised is spread over 18 months.
The company is raising capital through the issuance of convertible warrants to a promoter group entity, which is generally viewed positively as it can strengthen the company's financial position and support future growth.
Virinchi Limited has approved the allotment of 74,00,000 (Seventy Four Lakh) convertible equity warrants on a preferential basis to Vivo Bio Tech Limited, a promoter group entity. The allotment was approved by the Stakeholders Relationship Committee at its meeting held on Friday, January 09, 2026.
Each warrant is priced at ₹28, consisting of a face value of ₹10 and a premium of ₹18. The company has received 25% of the issue price, amounting to ₹7 per warrant, totaling ₹5,18,00,000 (Rupees Five Crore Eighteen Lakh only). The remaining 75% of the issue price, ₹21 per warrant, is due upon conversion into fully paid-up equity shares. These warrants are convertible into an equal number of equity shares within 18 months from the date of allotment. If not exercised within this period, the warrants will lapse, and the amount paid will be forfeited.
This issuance follows a special resolution passed by shareholders at an Extra-Ordinary General Meeting on November 15, 2025, and received in-principle approval from BSE and NSE on December 31, 2025. Post allotment, the paid-up share capital of the company remains unchanged.
What to do with a filing like this
Virinchi Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Virinchi Limited. Read the original for the full detail.